Faricimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Faricimab. Educational only — not medical advice.
Labeled uses
VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with:
Source: FDA labeling via NIH DailyMed (set 04cc9ef7…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.